

IN THE CLAIMS:

Please amend claim 1, without prejudice, to read as follows:

1. (Currently Amended) A transdermal system for the delivery of clonidine consisting essentially of:

 a pressure-sensitive contact adhesive layer ~~comprising~~ consisting of clonidine, ~~acrylate~~ and a copolymer, wherein said copolymer ~~comprises~~ consists of 2-ethylhexyl acrylate and vinyl acetate;

 a covering; and

 on a side opposite from the covering, a removable support that temporarily covers the contact adhesive layer.

16. (Currently Amended) The ~~T~~ransdermal system of claim 1 wherein the contact adhesive layer comprises clonidine in a concentration range of from 0.1 to 20% by weight.

17. (Currently Amended) The ~~T~~ransdermal system of claim 16 wherein the contact adhesive layer comprises clonidine in a concentration range of from 2 to 10% by weight.

18. (Currently Amended) The ~~T~~ransdermal system of claim 1 wherein the contact adhesive layer further comprises at least one element selected from the group consisting of fillers, skin-protective substances, and tackifiers.

19. (Currently Amended) A transdermal system comprising a planar self-adhesive patch of a multi-layered structure consisting essentially of:

 a clonidine-containing, pressure-sensitive, ~~acrylate-based~~ contact adhesive layer ~~comprising~~ consisting of a copolymer consisting of the monomers 2-ethylhexyl acrylate and vinyl acetate;

 a covering; and

on a side opposite from the covering a removable support that temporarily covers the contact adhesive layer.

20. (Cancelled).

21. (Currently Amended) The ~~T~~ransdermal system of claim 19 wherein the covering is selected from the group consisting of plastic film, plastic foam, woven fabric, and non-woven fabric.

22. (Currently Amended) The ~~T~~ransdermal system of claim 19 wherein the support is of plastic film, paper, or a laminate of plastic film and paper.

23. (Currently Amended) The ~~T~~ransdermal system of claim 22 wherein the support is siliconized.

24. (Currently Amended) The ~~T~~ransdermal system of claim 21 wherein the support comprises a polyester film, polyethylene film, or polypropylene film.

25. (Previously Presented) The transdermal system of claim 19 wherein the contact adhesive layer has a dry weight per unit area of from 20 g/m² to 150 g/m².

26. (Previously Presented) The transdermal system of claim 25 wherein the contact adhesive layer has a dry weight per unit area of from 50 g/m² to 120 g/m².

27. (Currently Amended) The ~~T~~ransdermal system of claim 1 wherein the delivery rate is from 10 µg to 1000 µg of clonidine per day.

28. (Currently Amended) The ~~T~~ransdermal system of claim 1 wherein the delivery rate is from 50 µg to 500 µg of clonidine per day.

29. (Currently Amended) A ~~M~~ethod of treating a disorder selected from the group consisting of hypertension, migraine, anxiety states, hyperkinetic behavioral disorders, withdrawal symptoms in alcohol or drug withdrawal, and menopausal symptoms, said method

comprising the step of administering clonidine to a patient in need of such treatment by transdermal delivery from the transdermal system of claim 1.

30. (New) A transdermal system for the delivery of clonidine consisting essentially of:

a pressure-sensitive contact adhesive layer consisting of clonidine and a copolymer, wherein said copolymer consists of 2-ethylhexyl acrylate and vinyl acetate;

a covering; and

on a side opposite from the covering, a removable support that temporarily covers the contact adhesive layer, wherein the concentration of said clonidine is in a range of from 0.1 to 20% by weight.